Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women

Gynecological Endocrinology

Volumn 18, Issue 5, 2004, Pages 244-257

  Christodoulakos, G E ^a,b   Lambrinoudaki, I V ^a   Panoulis, C P ^a   Papadias, C A ^a   Kouskouni, E E ^a   Creatsas, G C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

ERT; HRT; Lipid; Lipoprotein; Raloxifene; Tibolone

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREMELLE 5; RALOXIFENE; TIBOLONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; APOLIPOPROTEINS B; CHOLESTEROL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; GREECE; HUMANS; LIPIDS; LIPOPROTEIN(A); MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRIGLYCERIDES;

EID: 2942589253     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590410001715207     Document Type: Article

References (70)

1. Ossewaarde ME, Bots ML, Bak AA, et al. Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women. Maturitas 2001;39:209-16
2. Nazr A, Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of the iceberg. Gynecol Endocrinol 1998;12:43-59
3. Ylikorkala O, Lim P, Caubel P. Effects on serum lipid profiles of continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000;22:622-6
4. Chen FP, Lee N, Wang CH, et al. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998;69:267-73
5. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11
6. Mijatovic V, van der Mooren MJ, Stehouwer CD, et al. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol Endocrinol 1999;13:130-44
7. Christodoulakos G, Panoulis C, Kouskouni E, et al. Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis. Gynecol Endocrinol 2002;16:9-17
8. Shulman LP. Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women. Am J Cardiol 2002;89(Suppl):47E-55E
9. Kojima K, Abe-Dohmae S, Arakawa R, et al. Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta 2001;1532:173-84
10. Itoi H, Minekami H, Iwasaki R, et al. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early postmenopausal women. Maturitas 2000;36:217-22
11. The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33
12. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915
13. Sullivan JM, Fowles LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol 1996;87:365-435
14. Petitti DB. Hormone replacement therapy for prevention. More evidence, more pessimism. J Am Med Assoc 2002;288:1
15. Hulley S, Grady D, Bush T, et al., for the HERS Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-13
16. Hulley S, Furberg C, Barrett-Connor E, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Study follow-up (HERS II). J Am Med Assoc 2002;288:49-57
17. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks and benefits. Menopause 2002;9:6-15
18. Wild RA. Estrogen: effects on cardiovascular tree. Obstet Gynecol 1996;87:27S-35S
19. von Eckardstein A, Schmiddem K, Hovels A, et al. Lowering of HDL cholesterol in postmenopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis 2001;159:433-9
20. Mendoza N, Suarez AM, Alamo F, et al. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17β-estradiol for hormonal relacement therapy in women with surgical menopause. Maturitas 2000;37:37-43
21. Williams JK, Hall J, Anthony MS, et al. A comparison of tibolone and hormone replacement therapy on coronary artery and myocardial function in ovariectomized atherosclerotic monkeys. Menopause 2002; 9:41-51
22. Baracat EC, Barbosa IC, Giordano MG, et al. A randomised, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects of symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002:5:60-9
23. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22
24. Bergeron C. Microscopic evaluation of the effect of hormone replacement therapy on the endometrium in women who bleed. Gynecol Endocrinol 1997;11(Suppl 2):11-16
25. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four year results from the MORE Trial. J Am Med Assoc 2002;287:847-57
26. Nickelsen T, Creatsas G, Rechberger T, et al. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 2001:4:320-31
27. Christodoulakos G, Panoulis C, Botsis D, et al. Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. Maturitas 2002;42:77-84
28. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
29. Christodoulakos G, Lambrinoudaki I, Vourtsi A, et al. Mammographic changes associated with raloxifene and tibolone therapy: a prospective study. Menopause 2002;9:110-16
30. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women - results from the MORE randomized trial. J Am Med Assoc 1999;28:2189-97
31. Smolders RG, Vogelvang TE, Mijatovic V, et al. A 2-year randomized, comparative study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002;4:105-14
32. van Baal WM, Kenemans P, Emeis JJ, et al. Long term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999;71:663-70
33. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adult (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
34. Petridou E, Malamou H, Doxiadis S, et al. Blood lipids in Greek adolescents and their relation to diet, obesity and socioeconomic factors. Ann Epidemiol 1995;5:286-91
35. Benetou V, Chloptsios Y, Zavitsanos X, et al. Total cholesterol and LDL-cholesterol in relation to socioeconomic status in a sample of 11,645 Greek adults: the EPIC study in Greece. European Prospective Investigation into Nutrition and Cancer. Scand J Public Health 2000;28:260-5
36. Cruz JA. Dietary habits and nutritional status in adolescents over Europe - Southern Europe. Eur J Clin Nutr 2000;54(Suppl 1):S29-35
37. Kafatos A, Diacatou A, Voukiklaris G, et al. Heart disease risk factor status and dietary changes in the Cretan population over the past 30 years: the Seven Countries Study. Am J Clin Nutr 1997;65:1882-6
38. Voukiklaris GE, Kafatos A, Dontas AS. Changing prevalence of coronary heart disease risk factors and cardiovascular diseases in men of a rural area of Crete from 1960 to 1991. Angiology 1996;47:43-9
39. Keys A, Menotti A, Aravanis C, et al. The Seven Countries Study. 2289 deaths in 15 years. Prev Med 1984;13:141-54
40. Loh FH, Chen LH, Yu SL, et al. The efficacy of two dosages of a continuous combined hormone replacement regimen. Maturitas 2002;41:123-31
41. Sanada M, Nakagawa H, Kodama I, et al. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia. Metabolism 2000;49:784-9
42. Erenus M, Karakoc B, Gurler A. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 2001;4:228-34
43. West SG, Hinderliter AL, Wells EC, et al. Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women. Am J Obstet Gynecol 2001;184:926-33
44. Sanada M, Higashi Y, Nakagawa K, et al. Hormone replacement effects on endothelial function measured in the forearm resistance artery in normocholesterolemic and hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab 2002;87:4634-41
45. Palacios S. Tibolone: a tissue-specific approach to the menopause. Eur Heart J 2001;3(Suppl M):M12-16
46. Jackson G. Tibolone and the cardiovascular system. Eur Heart J 2001;3(Suppl M):M17-21
47. Crook D. Lipid predictors of coronary heart disease and tibolone users. Eur Heart J 2001;3(Suppl M):M22-6
48. Castelo-Branco C, Vicente JJ, Figueras F, et al. Two year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins A1 and B. Menopause 1999;6:22-7
49. Barnes JF, Farish E, Rankin M, et al. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis 2002;160:185-93
50. Blum A, Cannon RO. Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and hypercholesterolemic men. Ann NY Acad Sci 2001;949:168-74
51. Johnston CC, Bjarnason NH, Cohen FJ, et al. Long term effects of raloxifene on bone mineral density, bone turnover and serum lipid levels in early postmenopausal women: three-year data from 2 double blind randomized placebo-controlled trials. Arch Intern Med 2000;160:3444-50
52. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998;279:1445-51
53. Chen FP, Lee N, Soon YK, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. Menopause 2001;8:347-52
54. Zandberg P, Peters JLM, Demacker PNM, et al. Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits. Menopause 2001;8:96-105
55. Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estrogen/Progestin Intervention Study: primary outcomes in adherent women. Maturitas 1997;27:261-74
56. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204
57. Aygen EM, Basbug M, Tayyar M, et al. The effects of different doses of medroxyprogesterone acetate on serum lipids, lipoprotein levels and atherogenic index in the menopausal period. Gynecol Endocrinol 1998;12:267-72
58. Bisonette F, Lussier-Cacan S, Fugere P, et al. Metabolic effect of two hormonal preparations in postmenopausal women. Maturitas 1997;27:275-84
59. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6
60. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. J Am Med Assoc 1996;276:544-8
61. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997;157:1170-6
62. Kim CJ, Min YK, Ryu WS, et al. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med 1996;156:1693-700
63. Farish E, Barnes JF, Rolton HA, et al. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1994;20:215-19
64. Milner MH, Sinnott MM, Cooke TM, et al. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol 1996;87:593-9
65. Kearney CE, Purdie DW. Selective estrogen receptor modulators. Climacteric 1998;1:143-7
66. Mijatovic V, Van der Mooren MJ, Kenemans P, et al. Raloxifene lowers serum lipoprotein(a) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause 1999;6:134-7
67. Stevenson JC. Are changes in lipoproteins during HRT important? Br J Obstet Gynaecol 1996;103(Suppl 13):39-44
68. Haines CJ, Chung TK, Masarei JR, et al. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins. Atherosclerosis 1996;119:215-22
69. Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995;64:957-62
70. Tonstad S. Combined hormone replacement therapy with oestradiol and norethisterone acetate: effects in hyperlipidaemia. Br J Obstet Gynaecol 1996;103(Suppl 13):45-8